Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43841   clinical trials with a EudraCT protocol, of which   7281   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-002752-16
    Sponsor's Protocol Code Number:GCT3009-01
    National Competent Authority:Denmark - DHMA
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2020-01-21
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedDenmark - DHMA
    A.2EudraCT number2019-002752-16
    A.3Full title of the trial
    Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma – A First-in-Human, Open-label, Phase I/IIa Dose Escalation Trial with Dose Expansion Cohorts
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Safety and efficacy study of GEN3009-01 (DuoHexaBody®-CD37) in patients with B-cell Non-Hodgkin Lymphoma
    A.4.1Sponsor's protocol code numberGCT3009-01
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGenmab Holding B.V.
    B.1.3.4CountryNetherlands
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGenmab Holding B.V.
    B.4.2CountryNetherlands
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGenmab Holding B.V.
    B.5.2Functional name of contact pointClinical Trials Information
    B.5.3 Address:
    B.5.3.1Street AddressUppsalalaan 15
    B.5.3.2Town/ cityUtrecht
    B.5.3.3Post code3584 CM
    B.5.3.4CountryNetherlands
    B.5.4Telephone number+4570202728
    B.5.6E-mailclinicaltrials@genmab.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDuoHexaBody®-CD37
    D.3.2Product code GEN3009
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGEN3009
    D.3.9.1CAS number 2364496-42-2
    D.3.9.2Current sponsor codeDuoHexaBody®-CD37
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEpcoritamab
    D.3.2Product code DuoBody®-CD3xCD20
    D.3.4Pharmaceutical form Concentrate for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEpcoritamab
    D.3.9.1CAS number 2134638-15-4
    D.3.9.2Current sponsor codeDuoBody®-CD3xCD20
    D.3.9.3Other descriptive nameGEN3013
    D.3.9.4EV Substance CodeSUB190479
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEpcoritamab
    D.3.2Product code DuoBody®-CD3xCD20
    D.3.4Pharmaceutical form Concentrate for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEpcoritamab
    D.3.9.1CAS number 2134638-15-4
    D.3.9.2Current sponsor codeDuoBody®-CD3xCD20
    D.3.9.3Other descriptive nameGEN3013
    D.3.9.4EV Substance CodeSUB190479
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number60
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
    E.1.1.1Medical condition in easily understood language
    Non-Hodgkin Lymphoma (NHL)
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 22.0
    E.1.2Level PT
    E.1.2Classification code 10029547
    E.1.2Term Non-Hodgkin's lymphoma
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Dose Escalation (GEN3009 for R/R B-cell NHL Including CLL/SLL):
    - Determine the MTD with and/or determine the RP2D of GEN3009
    - Evaluate safety and tolerability of GEN3009

    Expansion (GEN3009 for R/R, DLBCL, FL, and CLL Cohorts):
    -Evaluate (preliminary) anti-tumor efficacy of GEN3009

    Expansion (GEN3009 + GEN3013 Safety Run-in for R/R B-NHL):
    -Identify the RP2D of GEN3009 + GEN3013 combination
    -Evaluate safety and tolerability of GEN3009 + GEN3013 combination

    Expansion (GEN3009 + GEN3013 for R/R DLBCL):
    -Assess preliminary anti-tumor activity of GEN3009 + GEN3013 combination
    E.2.2Secondary objectives of the trial
    Dose Escalation (GEN3009 for R/R B-cell NHL Including CLL/SLL):
    - Establish PK profile of GEN3009
    - Evaluate immunogenicity of GEN3009
    - Evaluate preliminary anti-tumor efficacy of GEN3009
    - Evaluate preliminary clinical efficacy of GEN3009

    Expansion (GEN3009 for R/R, DLBCL, FL, and CLL Cohorts):
    - Establish PK profile of GEN3009
    - Evaluate safety and tolerability of GEN3009
    - Evaluate clinical efficacy of GEN3009
    - Evaluate immunogenicity of GEN3009

    Expansion (GEN3009 + GEN3013 Safety Run-in for R/R B-NHL):
    - Establish the PK properties of GEN3009 and GEN3013
    - Evaluate immunogenicity
    - Assess the preliminary anti-tumor activity of GEN3009 + GEN3013 combination

    Expansion (GEN3009 + GEN3013 for R/R DLBCL):
    - Further assess the preliminary anti-tumor activity of GEN3009 + GEN3013 combination
    - Evaluate the safety and tolerability of GEN3009 + GEN3013
    - Establish the PK properties of GEN3009 and GEN3013
    - Evaluate immunogenicity
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Each potential subject must fulfill all of the following criteria to be enrolled in the trial.
    - Be at least 18 years of age.
    - Must sign an informed consent form (ICF) prior to any screening procedures.
    - Has histologically or cytologically confirmed relapsed or refractory B-cell NHL
    o For the dose escalation: with no available standard therapy or is not a candidate for available standard therapy. All subjects must have received at least 2 prior lines of systemic therapy, and,
    a. For all indolent NHL (FL, MZL, and SLL) as well as aggressive NHL (DLBCL, HGBCL, and PMBCL), at least 1 of the 2 prior lines of treatment must have been a CD20-containing systemic regimen;
    b. For MCL, subjects must have had or are otherwise ineligible for treatment with a BTK inhibitor, and;
    c. For CLL, subjects must have received at least 1 prior line of BTK inhibitor or BCL-2 inhibitor.
    o For the expansion (including Safety Run-in): All subjects must have received at least 2 prior lines of systemic therapy, and,
    a. For FL and DLBCL, at least 1 of the 2 prior lines of treatment must have been a CD20-containing systemic regimen;
    b. For CLL, subjects must have received at least one prior line of BTK inhibitor or BCL-2 inhibitor.
    - Has 1 of the following B-cell NHL subtypes for the Dose Escalation:
    o DLBCL, de novo or histologically transformed
    o HGBCL
    o PMBCL
    o FL, with advanced symptomatic disease and with a need for treatment
    o MCL, without leukemic manifestation
    o MZL, either nodal, extranodal, or mucosa associated, with a need for treatment initiation based on symptoms and/or disease burden
    o SLL, with a need for treatment based on symptoms and/or disease burden
    o CLL with active disease that needs treatment based on the International Workshop on Chronic Lymphocytic Leukemia [iwCLL] criteria)

    and the following B-cell NHL subtypes for the Expansion (including safety run-in):
    o DLBCL, de novo or histologically transformed
    o FL Grade 1, 2 and 3a, with advanced symptomatic disease and with a need for treatment initiation
    o CLL, must have active disease that needs treatment with at least 1 of the following criteria being met:
    a. Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia
    b. Massive (ie, ≥6 cm below the left costal margin) or progressive or symptomatic splenomegaly
    c. Massive nodes (ie, ≥10 cm in longest diameter) or progressive or symptomatic lymphadenopathy
    o GEN3009 + GEN3013 combination cohort only: Documented CD20+ DLBCL or FL based on representative pathology report
    - Has measurable disease for B-cell NHL or for CLL.
    - Has ECOG performance status of 0 or 1.
    - Has acceptable laboratory parameters.
    - A woman of reproductive potential must agree to use adequate contraception during the trial and for 12 months after the last GEN3009 and/or GEN3013 administration. Adequate contraception is defined as highly effective methods of contraception (refer to Appendix 12 for more information). In countries where 2 highly effective methods of contraception are required, both methods will be required for inclusion.
    - A woman of childbearing potential must have a negative serum beta-hCG at screening.
    - A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control and all men must also not donate sperm during the trial and for 12 months after receiving the last dose of GEN3009 and/or GEN3013.
    E.4Principal exclusion criteria
    Any potential subject who meets any of the following criteria will be excluded from participating in the trial.
    - Prior treatment with a CD37-targeting agent.
    - For the Expansion (including safety run-in): GEN3009 + GEN3013 combination cohort only: Prior treatment with a CD3 × CD20 bispecific antibody.
    - Prior allogeneic HSCT.
    - Autologous HSCT within 3 months before the first dose of GEN3009.
    - For the Expansion (including safety run-in): Lymphomas leukemia phase: high absolute lymphocyte count or the presence of abnormal cells in the peripheral blood indicating circulating lymphoma cells
    - Treatment with an anti-cancer biologic including anti-CD20 therapy, radio-conjugated or toxin-conjugated antibody or chimeric antigen receptor (CAR) T cell therapy within 4 weeks or 5 half-lives, whichever is shorter, before the first dose of GEN3009. Treatment with small molecules such as BTK inhibitors, BCL2 inhibitors, or PI3K inhibitors within 5 half-lives prior to the first dose of GEN3009.
    - Chemotherapy or radiation therapy within 2 weeks of the first dose of GEN3009.
    - Treatment with an investigational drug or an invasive investigational medical device within 4 weeks or 5 half-lives, whichever is shorter, prior to the first dose of GEN3009, and at any time during the study treatment period.
    - Received a cumulative dose of corticosteroids more than the equivalent of 250 mg of prednisone within the 2–week period before the first dose of GEN3009.
    - Has uncontrolled intercurrent illness (refer to Protocol Section 5.2 for details).
    - For the Expansion (including safety run-in): GEN3009 + GEN3013 combination cohort only: Seizure disorder requiring therapy (such as steroids or anti-epileptics)
    - Toxicities from previous anti-cancer therapies have not resolved to baseline levels or to Grade 1 or less except for alopecia and peripheral neuropathy.
    - Primary central nervous system (CNS) lymphoma or known CNS involvement at screening.
    - Has known past or current malignancy other than inclusion diagnosis (refer to Section 5.2 for details).
    - Had allergic reactions to anti-CD20 or anti-CD37 monoclonal antibody treatment or intolerant to GEN3009 excipients (refer to the GEN3009 IB for more information).
    - For the Expansion (including safety run-in): Intolerant to GEN3013 excipients (refer to the GEN3013 IB for more information).
    - Has had major surgery, (eg, requiring general anesthesia) within 4 weeks before screening or will not have fully recovered from surgery, or has major surgery planned during the time the subject is expected to participate in the trial (or within 4 weeks after the last dose of GEN3009 and/or GEN3013).
    - Has known history/positive serology for hepatitis B.
    - Known medical history or ongoing hepatitis C infection that has not been cured.
    - Known history of seropositivity for HIV infection.
    - Is a woman who is pregnant or breast-feeding, or who is planning to become pregnant while enrolled in this trial or within 12 months after the last dose of GEN3009 and/or GEN3013.
    - Is a man who plans to father a child while enrolled in this trial or within 12 months after the last dose of GEN3009 and/or GEN3013.
    - Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments. Additionally, vulnerable subjects or subjects under guardianship, curatorship, judicial protection or deprived of liberty), are excluded from participation in this trial.
    - Prior treatment with live, attenuated vaccines within 4 weeks prior to initiation of GEN3009.
    Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. Experimental and/or non-authorized SARS-CoV-2 vaccinations are not allowed.
    - Dose escalation only: Lymphomas leukemia phase: high absolute lymphocyte count or the presence of abnormal cells in the peripheral blood indicating circulating lymphoma cells.
    E.5 End points
    E.5.1Primary end point(s)
    Dose Escalation (GEN3009 for R/R B-cell NHL Including CLL/SLL):
    • Rate of DLTs
    • Frequency and severity of adverse events (AEs)/AESIs/SAEs
    • Changes in laboratory parameters
    • Changes in vital signs
    • Frequency of dose interruptions, dose delays, and dose intensity

    Expansion(GEN3009 for R/R, DLBCL, FL, and CLL Cohorts):
    • ORR

    Expansion (GEN3009 + GEN3013 Safety Run-in for R/R B-NHL):
    • Rate of DLTs
    • Frequency and severity of AEs/AESIs/SAEs
    • Changes in laboratory parameters
    • Changes in vital signs
    • Frequency of dose interruptions, dose delays, and dose intensity

    Expansion (GEN3009 + GEN3013 for R/R DLBCL):
    • CR rate
    E.5.1.1Timepoint(s) of evaluation of this end point
    During the trial, see protocol
    E.5.2Secondary end point(s)
    Dose Escalation (GEN3009 for R/R B-cell NHL Including CLL/SLL):
    • PK parameters: clearance, volume of distribution and area under the curve (AUC) at different time points (AUC7days, AUClast and AUCinf), maximum concentration (Cmax), time to Cmax (Tmax), predose trough concentrations (Ctrough), and half-life (T1/2)
    • Incidence of neutralizing anti-GEN3009 antibodies (ie, ADAs)
    • ORR
    • CR rate
    • DoR
    • TTR
    • PFS
    • OS

    Expansion (GEN3009 for R/R, DLBCL, FL, and CLL Cohorts):
    • PK parameters: CL, AUC7days, AUClast, Cmax, Tmax, Ctrough, and T1/2
    • Frequency and severity of AEs/AESIs/SAEs
    • Changes in laboratory parameters
    • Changes in vital signs
    • Frequency of dose interruptions, dose delays, and dose intensity
    • CR rate
    • DoR
    • TTR
    • PFS
    • OS
    • Incidence of neutralizing anti-GEN3009 antibodies (ie, ADAs)

    Expansion (GEN3009 + GEN3013 Safety Run-in for R/R B-NHL):
    • PK parameters: CL, AUC7days, AUClast, Cmax, Tmax, Ctrough, and T1/2
    • Incidence of neutralizing ADAs to GEN3009
    • Incidence of neutralizing ADAs to GEN3013
    • CR rate
    • ORR
    • DoR
    • TTR
    • PFS
    • OS

    Expansion (GEN3009 + GEN3013 for R/R DLBCL):
    • ORR
    • DOR
    • TTR
    • PFS
    • OS
    • Rate and duration of MRD negativity
    • Frequency and severity of AEs/AESIs/SAEs
    • Changes in laboratory parameters
    • Changes in vital signs
    • Frequency of dose interruptions, dose delays, and dose intensity
    • PK parameters: CL, AUC7days, AUClast, Cmax, Tmax, Ctrough, and T1/2
    • Incidence of neutralizing ADAs to GEN3009
    • Incidence of neutralizing ADAs to GEN3013
    E.5.2.1Timepoint(s) of evaluation of this end point
    During the trial, see protocol
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Immunogenicity
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans Yes
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Different doses of GEN3009
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA28
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United States
    Belgium
    Denmark
    France
    Netherlands
    Spain
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The trial is considered completed when the last subject dies or withdraws from the trial. However, the maximum trial duration is 5 years after the last subject’s first treatment in the trial.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days1
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 109
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 73
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state19
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 109
    F.4.2.2In the whole clinical trial 182
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Following trial termination, the sponsor will make their best effort to ensure provision of post-trial access to GEN3009 and/or GEN3013 for those ongoing trial subjects with a potential treatment benefit, in accordance with local laws and requirements.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-03-13
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-11-17
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2023-07-28
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA